MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection

Author: O'Hagan, Derek T

Source: Expert Review of Vaccines, Volume 6, Number 5, October 2007 , pp. 699-710(12)

Buy & download fulltext article:

Price: $73.00 plus tax (Refund Policy)

Abstract:

In preclinical studies, MF59 adjuvant offered improved protection against influenza virus challenge and significantly reduced the viral load in the lungs of challenged mice. In humans, MF59 is a safe and potent vaccine adjuvant that has been licensed in more than 20 countries (Fluad^® [Novartis Vaccines and Diagnostics Inc., MA, USA]). The safety profile of an MF59-adjuvanted vaccine is well established through a large safety database. MF59 adjuvant has had a significant impact on the immunogenicity of influenza vaccines in the elderly and in adults who are chronically ill. MF59 has also been shown to have a significant impact on the immunogenicity of pandemic influenza vaccines. MF59 allows for broader cross-reactivity against viral strains not included in the vaccine. MF59 has been shown to be more potent for both antibody and T-cell responses than aluminum-based adjuvants. MF59 has broad potential to be used as a safe and effective vaccine adjuvant for a wide range of vaccine types.

Keywords: improved influenza vaccines; MF59 adjuvant; oil-in-water emulsion; vaccine adjuvant

Document Type: Research article

DOI: http://dx.doi.org/10.1586/14760584.6.5.699

Publication date: 2007-10-01

More about this publication?

Expert Review of Vaccines provides expert reviews on the clinical effectiveness of new vaccines. Coverage includes vaccine technology, vaccine adjuvants, prophylactic vaccines, therapeutic vaccines, AIDS vaccines and vaccines in bioterrorism.
Editorial Board
Information for Authors
Submit a Paper
Subscribe to this Title
Information for Advertisers
Terms & Conditions
Information for Librarians
Free Trials
ingentaconnect is not responsible for the content or availability of external websites